ABEONA THERAPEUTICS INC. (NASDAQ:ABEO) Files An 8-K Other Events
Item 8.01.
On December 19, 2019, Abeona Therapeutics Inc. issued a press release entitled “Abeona Therapeutics Announces Public Offering of Common Stock and Pre-Funded Warrants.” The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
(d) Exhibits.
| 99.1 | Press release dated December 19, 2019, entitled “Abeona Therapeutics Announces Public Offering of Common Stock and Pre-Funded Warrants.” |
ABEONA THERAPEUTICS INC. Exhibit
EX-99.1 2 tm1926696d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Abeona Therapeutics Announces Public Offering of Common Stock and Pre-Funded Warrants NEW YORK and CLEVELAND,…
To view the full exhibit click here
About ABEONA THERAPEUTICS INC. (NASDAQ:ABEO)
Abeona Therapeutics, Inc. (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc., is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. The Company is also developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD), and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a clustered, regularly interspaced short palindromic repeats (CRISPR)/Cas9-based gene editing approach to gene therapy program for rare blood diseases. It is developing rare plasma protein therapies, including PTB-101 SDF Alpha (alpha-1 protease inhibitor) for inherited chronic obstructive pulmonary disease. Its product pipeline also consists of MuGard and ProdiGard.
